Hengartner H, Berger C, Nadal D, Niggli F K, Grotzer M A
Division of Oncology, University Children's Hospital of Zurich, Steinwiesstrasse 75, Zurich 8032, Switzerland.
Eur J Cancer. 2004 Nov;40(16):2452-8. doi: 10.1016/j.ejca.2004.07.017.
Implanted subcutaneous (s.c.) central venous port accesses including Port-A-Cath (PAC) facilitate the administration of chemotherapy or blood products and are frequently used in children with cancer. The incidence of PAC-related infections was determined in 155 consecutive paediatric cancer patients with PAC followed for a total of 134,773 days (median, 738; range, 25-2080). Overall, 48 bloodstream infections occurred in 26 patients. 12 (25%) of these infections and 3 local infections at the insertion site were treatment-resistant and demanded removal of the PAC. Coagulase-negative staphylococci were involved in 12 of these 15 episodes. The rate of clearly PAC-related infections in this so far largest reported series was 0.11 episodes per 1000 PAC days, one of the lowest in the literature. Although catheter-related infections demanded PAC removal in 8% of our patients, the long periods PAC were in use and their benefits argue for continued PAC use in the paediatric cancer population.
植入式皮下中心静脉端口通路,包括Port - A - Cath(PAC),便于化疗药物或血液制品的输注,常用于患癌儿童。在155例连续使用PAC的儿科癌症患者中确定了PAC相关感染的发生率,这些患者共随访134,773天(中位数738天;范围25 - 2080天)。总体而言,26例患者发生了48次血流感染。其中12例(25%)感染以及3例插入部位的局部感染耐药,需要移除PAC。这15次感染中有12次涉及凝固酶阴性葡萄球菌。在这个迄今为止报道的最大系列研究中,明确的PAC相关感染率为每1000个PAC日0.11次,是文献中最低的之一。尽管8%的患者因导管相关感染需要移除PAC,但PAC的长期使用及其益处表明应继续在儿科癌症患者中使用PAC。